Login to Your Account

Clinic Roundup

Tuesday, April 10, 2012
• RedHill Biopharma Ltd., of Tel Aviv, Israel, said initial analysis of a pharmacokinetic study comparing its version of odansetron with Zofran (odansetron, GlaxoSmithKline plc) showed the trial met its objective of establishing bioequivalence. Assuming the final clinical study report supports the preliminary findings, RedHill said it will consider filing for U.S. marketing approval.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription